Manufacturing facility to provide 1.5 million square feet of bioproduction technologies
Thermo Fisher Scientific Inc., a contract development and manufacturing organization (CDMO), will be now be operating a new biologics manufacturing site in Lengnau, Switzerland as part of its strategic partnership with Austrailian biotech company CSL Limited announced last year. The Lengnau site will become part of Thermo Fisher’s global biologics manufacturing network, and approximately 200 employees will join the Thermo Fisher team.
The Lengnau site is a 1.5 million square-foot facility that will feature highly flexible bioproduction technologies, such as single-use and stainless steel with up to 12,500L bioreactor capacity. This will provide biopharma companies with a pathway from development to large-scale production as one’s manufacturing needs develop.
Site construction is expected to be completed in 2022.
“We are excited to add the new Lengnau site to our global biologics manufacturing network, and we are thrilled to welcome more than 200 new colleagues to Thermo Fisher,” notes Michel Lagarde, Thermo Fisher Scientific’s executive vice president. “Through our partnership with CSL, this site further strengthens our unique customer value proposition to leverage our scale and depth of capabilities for pharma and biotech customers.”